Background Despite the limited evidence in immunocompromised populations, the U.S. Food and Drug Administration issued an Emergency Use Authorization in December 2021 for tixagevimab/cilgavimab (T/C) indicated for COVID-19 pre-exposure prophylaxis. T/C has been used widely at our center, therefore, we sought to determine the safety and effectiveness of T/C for this indication in a cohort of kidney transplant recipients. Methods This was a retrospective, single-center, Institutional Review Board-approved study evaluating the outcomes of 122 kidney transplant recipients who received tixagevimab/cilgavimab for pre-exposure prophylaxis of COVID-19. Adult patients who received T/C between January 1 ^st, 2022 and March 31 ^st, 2022 were reviewed for inclusion. The efficacy population (n= 115) comprised those who received two doses and the safety population (n=122) comprised those who received any amount of T/C. The primary outcome was the rate of hospitalization for COVID-19 infection within six months of the first dose of T/C. The secondary outcome was serious adverse events attributed to T/C. Results Within six months of administration, low rates of hospitalization (2%) and adverse events (2%) were found, with no incidence of heart failure, myocardial infarction, or anaphylaxis. Conclusion Overall, our study demonstrated that T/C in kidney transplant recipients was safe and associated with low rates of hospitalization for COVID-19 infection when susceptible Omicron subvariants were dominant.